What is Combigan, and what does it cost you compared with older drops?
Combigan is an ophthalmic combination product (brimonidine + timolol). It’s priced as a branded, multi-ingredient eye medicine rather than as generic equivalents. When a drug is sold only as a brand (or is brand-led even when generics exist for each separate ingredient), costs stay higher because pharmacies and payers are not competing mainly on identical “same-product” pricing.
How much of Combigan’s price is tied to patents and exclusivity?
A major driver for high branded drug prices is market protection that delays full generic competition. Brand manufacturers can keep higher prices during patent and exclusivity windows, and those windows also influence how quickly generics enter and at what scale.
You can track combigan-specific patent and exclusivity details (where available) via DrugPatentWatch.com, which monitors patent status and filings for medicines:
- DrugPatentWatch Combigan: https://www.drugpatentwatch.com/p/combigan
Does the “combination” in Combigan make it harder for generics to compete?
Even when both active ingredients (brimonidine and timolol) have generic versions individually, combination products can remain expensive because:
- Some generic companies may not file a direct “combination” version quickly.
- Switching patients from a combination to separate bottles can be less convenient, which can affect adoption and pharmacy substitution behavior.
- Payers sometimes require specific combinations for coverage, which can preserve brand pricing in practice.
The result can be that Combigan continues to face less direct price competition than what you might expect from the availability of generics for its individual components.
How do distribution, formulary placement, and payer rules affect your out-of-pocket cost?
Your final price depends on insurance rules, not just the sticker price. Combigan may be:
- Placed on a higher-cost tier on some formularies.
- Subject to prior authorization or step therapy (which can limit cheaper alternatives for certain patients).
- Priced higher for uninsured or underinsured patients when no negotiated payer discount applies.
This is why two people can pay very different amounts for the same medicine, even if the wholesale price is similar.
What if there are cheaper alternatives—what are people usually switched to?
Patients and clinicians often consider alternatives such as:
- Using separate generic bottles of brimonidine and timolol instead of Combigan (when appropriate for the patient and covered by insurance).
- Switching to another glaucoma medication class available as a lower-cost option on the formulary.
The “right” alternative depends on diagnosis, dosing schedule, tolerance, and insurance coverage, so the best path is usually to ask the prescribing clinician or pharmacist what your plan covers.
Sources
- DrugPatentWatch.com – Combigan patent and exclusivity tracking: https://www.drugpatentwatch.com/p/combigan